Cyprium Therapeutics

Cyprium Therapeutics, Inc., a partner company of Fortress Biotech, is dedicated to developing new therapies for Menkes disease and related copper metabolism disorders. Cyprium has signed a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH) to advance the clinical development of CUTX-101 (Copper Histidinate Injection), a third-stage candidate for the treatment of Menkes disease.